ACE-mR-CoV - Development, testing and production of a SARS-CoV-2 vaccine based on mRNA technology.

The project encompasses all activities required for the approval and dissemination of a vaccine against SARS-CoV-2. In particular, this includes a broad phase I-III clinical programme to ensure the safety and effectiveness of the vaccine. In addition, the project includes the non-clinical studies relevant for approval as well as the increase of production capacities in order to make the vaccine available to a large part of the population in a timely manner after approval. After completion and evaluation of the ongoing phase I trial in autumn 2020, the clinical trials of phases II and III will follow. The goal of the vaccine development is a conditional approval of the vaccine by the European Medicines Agency (EMA), if possible already at the beginning of 2021, followed by the regular approval in the second half of 2021. In parallel, the production capacities for vaccine manufacturing will be expanded.